Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Affimed n.v. save search
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
Published: 2023-12-11 (Crawled : 11:00) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 1.19%
H: 1.18%
C: -13.29%
afm24 lung positive cancer cell
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
Published: 2023-03-29 (Crawled : 11:00) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 0.52%
H: 13.94%
C: 8.23%
afm28 treatment leukemia
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors
Published: 2022-04-08 (Crawled : 18:00) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: -0.21%
H: 1.27%
C: -5.94%
afm24
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
Published: 2021-12-09 (Crawled : 12:00) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 4.4%
H: 0.44%
C: -9.16%
cd30 treatment blood positive oda
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas
Published: 2021-11-22 (Crawled : 12:30) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 5.31%
H: 2.94%
C: -1.26%
blood phase 1 positive
Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis
Published: 2021-03-10 (Crawled : 12:00) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 14.26%
H: 17.6%
C: 8.32%
positive
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma
Published: 2020-12-07 (Crawled : 15:02) - globenewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 5.69%
H: 18.94%
C: 13.97%
positive
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.